GSK gets EC approval for new administration options of asthma treatment Nucala
GlaxoSmithKline (GSK) has secured marketing authorisation from the European Commission (EC) for two new administration options of Nucala (mepolizumab) to treat patients with severe eosinophilic asthma. Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma at